Cassava Sciences Announces Fireside Chat and Presentation Tuesday, April 5th

2 years ago

– CEO Remi Barbier to Discuss Q1 2022 Clinical and Corporate Updates – – Stakeholders Are Invited to Submit Questions…

Rendever Named to TIME’s List of the 2022 TIME100 Most Influential Companies

2 years ago

The Boston-based virtual reality company helps seniors worldwide overcome social isolation and improve mental health through its social metaverse platformsBOSTON,…

Prof. Avi Schroeder Joins SciSparc’s Scientific Advisory Board to Support the Company’s Development of SCI-160 for Treating Pain

2 years ago

Prof. Schroeder to advise on SCI-160 formulation development to enhance biological effect and extended effect duration TEL AVIV, Israel, March…

IBN (InvestorBrandNetwork) Coverage Initiated for Silo Pharma Inc.

2 years ago

NEW YORK, March 30, 2022 (GLOBE NEWSWIRE) -- via InvestorWire – Silo Pharma Inc. (OTCQB: SILO), a developmental stage biopharmaceutical…

Shockwave Medical Announces Japanese Regulatory Approval of Coronary IVL

2 years ago

Transformative Shockwave C2 Intravascular Lithotripsy Catheter Will Soon Be Available in One of the World’s Largest Coronary Intervention Markets SANTA…

CytoDyn to Hold Webcast to Provide Company Update

2 years ago

VANCOUVER, Washington, March 30, 2022 (GLOBE NEWSWIRE) --  CytoDyn Inc. (OTCQB: CYDY) ("CytoDyn" or the "Company"), a late-stage biotechnology company…

Acer Therapeutics Enrolls First Patient in its Phase 2a Clinical Trial of ACER-801 for Treatment of Moderate to Severe Vasomotor Symptoms Associated with Menopause

2 years ago

Results anticipated in H2 2022NEWTON, Mass., March 30, 2022 (GLOBE NEWSWIRE) -- Acer Therapeutics Inc. (Nasdaq: ACER), a pharmaceutical company…

Exagen Inc. Expands In-Network Access with Evolutions Healthcare Systems

2 years ago

SAN DIEGO, March 30, 2022 (GLOBE NEWSWIRE) -- Exagen Inc. (Nasdaq: XGN), a leading provider of autoimmune testing solutions, announced today that…

VectivBio Announces Japan License Deal and Loan Facility Agreement, Providing up to $117 Million to Fuel the Company Through Key Catalysts

2 years ago

Exclusive License with Asahi Kasei Pharma to develop and commercialize Apraglutide in Japan includes $30 million upfront cash payment, eligibility…

Collegium Announces Master Settlement Agreement Resolving Pending Opioid-Related Litigation

2 years ago

STOUGHTON, Mass., March 30, 2022 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (Nasdaq: COLL) today announced the execution of a Master…